As myriad pharma industry attempts to challenge the Inflation Reduction Act fall flat, Johnson & Johnson is settling into a reality of pricing rebates and Medicare drug cost negotiations.
Fierce Pharma
Internet News
New York, New York 90,731 followers
Pharma’s go-to destination for news & trends shaping approved drugs.
About us
Fierce Pharma is the go-to destination for the news and trends shaping the industry. Our focus daily is on news about approved drugs and every aspect of pharma’s operations as well as the people who move pharma forward. Our coverage also feeds longer-form content, podcasts and events. In staying on top of the news, our journalists have developed a loyal audience. Critically, we explain the news—often complicated technology or business maneuvers—and put it in context that brings it home for our readers and listeners in their work lives. Delivering news, revealing insights straight to your inboxes: https://fiercepharma.questexinfo.com/loading.do?omedasite=Pharma_full. Our family of publications includes Fierce Pharma, Fierce Pharma PM Tracker, Fierce Pharma Marketing, Fierce Manufacturing, Fierce Drug Delivery and Fierce Life Sciences Weekly Digest. Follow our podcast ‘The Top Line’ on Apple Podcasts, Spotify, Amazon, iHeart or wherever you get your podcasts. We dig into high-impact trends and recount the week’s biggest headlines. For Biotech news you can’t miss: https://www.linkedin.com/showcase/fierce-biotech For Healthcare news you can’t miss: https://www.linkedin.com/showcase/fierce-healthcare
- Industry
- Internet News
- Company size
- 51-200 employees
- Headquarters
- New York, New York
- Type
- Privately Held
- Founded
- 2006
Locations
-
Primary
685 3rd Ave
21st Floor
New York, New York 10017, US
Employees at Fierce Pharma
Updates
-
With a chemo-free regimen, Bayer hopes to reach the entire space of metastatic hormone-sensitive prostate cancer.
Bayer’s Nubeqa, en route to blockbusterland, clinches 2nd win in prostate cancer subtype
fiercepharma.com
-
The breadth of problems uncovered by the FDA is surprising considering the plant has been producing camrelizumab for the Chinese market since 2019.
Behind Hengrui's surprise FDA rejection: Scathing Form 483 lists litany of shortfalls at PD-1 drug plant
fiercepharma.com
-
CordenPharma will invest 900 million euros ($981 million) over the next three years to bolster its ability to manufacture GLP-1 peptides in Europe and the United States.
Swiss CDMO CordenPharma invests $981M to boost GLP-1 manufacturing capacity
fiercepharma.com
-
Eli Lilly and Company has choreographed another part of its Olympics-focused marketing campaign, partnering with seven-time medalist Simone Biles and her mom Nellie to promote the GLP-1 diabetes drug Mounjaro.
Eli Lilly vaults Simone Biles to head of Mounjaro ad campaign, partnering with Olympian for TV spot
fiercepharma.com
-
While patent cliffs are looming for many of biopharma’s top-selling products, the industry has enormous capacity to respond as “conditions for M&A are favorable,” according to a research note from Morgan Stanley.
Amgen, BMS and Merck have the most exposure as Big Pharma eyes $183B patent cliff: analyst
fiercepharma.com
-
Trials have already shown that Novo Nordisk’s semaglutide can cut the risk of cardiovascular events and kidney disease. Now a study from the University of Oxford indicates that the company’s semaglutide type 2 diabetes drug Ozempic can reduce the risk of dementia compared with another popular diabetes medicine.
Novo Nordisk's Ozempic cuts dementia risk compared with Merck's Januvia: Oxford study
fiercepharma.com
-
It’s well known that obesity drugs from Novo Nordisk and Eli Lilly are on a high-flying growth trajectory that doesn’t look to be letting up anytime soon. But, according to a new report from Evaluate, obesity products are set to take over many familiar stalwarts on the world’s top-selling drugs list by the end of the decade.
Move over, oncology: Obesity, diabetes meds will take over 2030's top drug rankings, Evaluate forecasts
fiercepharma.com
-
Novo Nordisk has won approval in Europe, Canada and Japan for its once-weekly insulin icodec. But the FDA has rejected it for manufacturing issues.
Citing manufacturing issue, FDA rejects Novo Nordisk's once-weekly insulin
fiercepharma.com
-
While much of the attention on Novo Nordisk these days revolves around the company’s wildly popular GLP-1 drugs Ozempic and Wegovy, insulin remains a critical backbone for the drugmaker.
Amid GLP-1 boom, Novo Nordisk strikes up insulin partnership in Indonesia
fiercepharma.com